A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation

NCT02659735 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza A Virus

Interventions

DRUG: JNJ-63623872 300 milligram (mg)
DRUG: JNJ-63623872 600 mg
DRUG: JNJ-63623872 600 mg
DRUG: JNJ-63623872 600 mg

Sponsor

Janssen Research & Development, LLC